Aethlon Medical, Inc. (AEMD) Q1 2027 Earnings Call Transcript
Aethlon Medical, Inc. (AEMD) Q4 2026 Earnings Call Transcript
Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 0.2 | $2.77 | $0.29 | -$2.48 | -89.53% |
| Health Care Technology Industry | Healthcare Sector | James Frakes CEO | NASDAQ (CM) Exchange | 00808Y604 CUSIP |
| US Country | 9 Employees | - Last Dividend | 4 Aug 2026 Last Split | 2 Jan 2001 IPO Date |
Aethlon Medical, Inc. is a pioneering medical therapeutic company based in San Diego, California, with a vital focus on developing innovative products aimed at treating cancer and life-threatening infectious diseases. Established in 1999, Aethlon is at the forefront of advancing immunotherapeutic devices in the clinical stage, targeting the removal of tumor-derived exosomes and life-threatening viruses from the human circulatory system. This effort signifies a groundbreaking approach to addressing some of the most challenging medical conditions faced today in the United States.